Englander Institute for Precision Medicine
AML Cells

Patients with acute myeloid leukemia (AML) may have genetic mutations in their blood indicating they are at high risk of developing the disease about nine years before diagnosis, according to research from Weill Cornell Medicine and NewYork-Presbyterian investigators. They presented their findings at the 59th annual American Society of Hematology meeting Dec. 10 in Atlanta.

“We never thought we could detect mutations at high frequency so many years prior to development...

Photo: EIPM

The Englander Institute for Precision Medicine (EIPM) has developed unique models to study cancer in its laboratories, such as growing mini tumors called ‘organoids’.

Human cancer tissue that is grown into organoids in the laboratory could be used to test drug responses and to personalize therapy.
Organoids can be made to resemble organs or tissues such as gut, kidney, pancreas, liver, breast, prostate, and even brain tissue, all complete with accurate micro-anatomy.

Due to...

Photo: EIPM

Precision medicine harnesses a unique mix of personal genetic, genomic and clinical information to inform patients’ medical care, for both treatment and prevention of diseases. This information includes individual genomic DNA sequences, which can potentially identify variants that cause disease, and in some cases predict how a patient will respond to a particular drug.

All cancers are...